VTVT vTv Therapeutics Inc - Ordinary Shares - Class A
15,144
$27.90
$0.02
(0.07%)
| Watchers | 15,144 |
| 52-Wk Low | $7.38 |
| 52-Wk High | $39.60 |
| Market Cap | $67.88M |
| Volume | 6,628.00 |
| 52-Wk High | $39.60 |
| 52-Wk Low | $7.38 |
vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Growth in Short InterestZolmax • about 2 months ago
vTv Therapeutics Inc. (NASDAQ:VTVT Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 57,200 shares, a growth...
Share to Feed
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire WESTON, Fla...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy...
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
Gagnants
Le titre vTv Therapeutics (NASDAQ:VTVT) a grimp mercredi de 57,06% 13,35 dollars lors de la session pre-market.
L'action Applied Therapeutics (NASDAQ:APLT) a mont de 52,32% 8,50...
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical...
vTv Therapeutics Inc. (NASDAQ:VTVT Get Free Report)s share price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $9.32...
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE PR Newswire WESTON, Fla., Feb. 22, 2024 WESTON...